Bladder monitor for detecting cancer return
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a urine test that may help find bladder cancer early without needing invasive procedures. It is for people with high-grade or high-risk non-muscle-invasive bladder cancer who are receiving or have received BCG treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have high-grade or high-risk bladder cancer that has not invaded the muscle layer.
- You are currently receiving or have previously received BCG treatment.
- You are able to undergo surgery if needed.
- You have not taken part in other trials involving chemotherapy or immunotherapy drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new blood test that looks for signs bladder cancer may be coming back in people with a recent history of bladder cancer. It may help by making surveillance easier, but you must still follow a scheduled bladder-check plan.
This trial tests a new urine test (BCDx) to see if it can catch bladder cancer coming back in people with non-muscle invasive bladder cancer (NMIBC) who are already having regular check-ups. You would give a urine sample before your routine cystoscopy, and the results may help doctors monitor your cancer more easily.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This study tries to predict whether BCG treatment will work for people with certain early-stage bladder cancers. It may help doctors better choose and monitor BCG for similar patients in the future.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.